Information Provided By:
Fly News Breaks for July 12, 2019
AIMT
Jul 12, 2019 | 14:13 EDT
Roth Capital analyst Zegbeh Jallah resumed coverage of Aimmune with a Buy rating and $45 price target, citing his view that AR101 could be a $1B+ opportunity despite debate on the commercial opportunity, especially following the ICER report that was recently published. After having recently sat down with management, he said commercial preparations are continuing at full speed, which Jallah called "a strong indication of management's confidence."
News For AIMT From the Last 2 Days
There are no results for your query AIMT